The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Wrt the "...a major license deal that could generate a transformational, non-dilutive, upfront payment of tens of millions of dollars." section.
This isn't new and goes back at least as far as Oct 2019 as it was included in the "Interim Results for the Period Ended 31 July 2019"
See:
https://avacta.com/interim-results-for-the-period-ended-31-july-2019/
Change to Therapeutics page just uploaded.
Not sure what it means to us...
Old: https://web.archive.org/web/20210201170657/https://avacta.com/therapeutics/
New: https://avacta.com/therapeutics/
Just udated: https://avacta.com/diagnostics/products/
From what I can tell the changes are:
Features and Benefits point altered:
Validated Against Delta Variant – Routine monitoring of all emerging variants to ensure continued diagnostic accuracy
Features and Benefits point added:
Environmentally-Friendly Packaging – Cardboard kit box can be recycled after use
Addition to Clinical Evaluation:
*Clinical evaluation study conducted at Hospital Carlos III and Hospital Universitario La Paz, Madrid, Spain between March-April 2021 using samples from patients with a recently confirmed SARS-CoV-2 RT-qPCR test result, from a variety of settings including hospital in-patients, walk-in test centres and participants in epidemiological studies.
@Richob
That's been there for more than a year now I'm afraid.
Nothing new: https://web.archive.org/web/20200524023359/https://avacta.com/about/
Only difference on today's update to https://avacta.com/investors/key-information/ is the following:
Today's page:
Conifer Management, LLC – 2.99%
As at 23rd July 2021 the company has 253,653,078 ordinary shares of 10p each in issue.
25th May update:
Conifer Management, LLC – 3.54%
As at 25th May 2021 the company has 253,424,204 ordinary shares of 10p each in issue.
Just to make my post above a little easier to read:
Contacts
Contact: Avacta Life Sciences +44 (0)1904 21 7070 clinicaltrials@avacta.com
Locations
United Kingdom
The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde
Glasgow, United Kingdom, G12 0YN
Principal Investigator: Professor Jeff Evans
St James's University Hospital, The Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom, LS9 7TF
Principal Investigator: Professor Chris Twelves
The Royal Marsden, NHS Foundation Trust
London, United Kingdom, SM2 5PT
Principal Investigator: Professor Udai Banerji
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Principal Investigator: Dr Natalie Cook
The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust
Newcastle upon Tyne, United Kingdom, NE7 7DN
Principal Investigator: Professor Ruth Plummer
Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom, S10 2SJ
Principal Investigator: Dr Robin Young
Sponsors and Collaborators
Avacta Life Sciences Ltd
More Information
Go to sections
Responsible Party: Avacta Life Sciences Ltd
ClinicalTrials.gov Identifier: NCT04969835 History of Changes
Other Study ID Numbers: ALS-6000-101
First Posted: July 21, 2021 Key Record Dates
Last Update Posted: July 21, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Qualified researchers may request access to individual patient-level data through clincialtrials@avacta.com
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Sarcoma
Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
From https://www.clinicaltrials.gov/ct2/show/study/NCT04969835#contacts:
Contacts
Contact: Avacta Life Sciences +44 (0)1904 21 7070 clinicaltrials@avacta.com
Locations
United Kingdom
The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde
Glasgow, United Kingdom, G12 0YN
Principal Investigator: Professor Jeff Evans
St James's University Hospital, The Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom, LS9 7TF
Principal Investigator: Professor Chris Twelves
The Royal Marsden, NHS Foundation Trust
London, United Kingdom, SM2 5PT
Principal Investigator: Professor Udai Banerji
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Principal Investigator: Dr Natalie Cook
The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust
Newcastle upon Tyne, United Kingdom, NE7 7DN
Principal Investigator: Professor Ruth Plummer
Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom, S10 2SJ
Principal Investigator: Dr Robin Young
Sponsors and Collaborators
Avacta Life Sciences Ltd
More Information
Go to sections
Responsible Party: Avacta Life Sciences Ltd
ClinicalTrials.gov Identifier: NCT04969835 History of Changes
Other Study ID Numbers: ALS-6000-101
First Posted: July 21, 2021 Key Record Dates
Last Update Posted: July 21, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Qualified researchers may request access to individual patient-level data through clincialtrials@avacta.com
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Sarcoma
Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Just published:
https://avacta.com/wp-content/uploads/2021/06/Avacta-Initiation-210629.pdf
I'm sure most of you have seen this but I kept skipping over it on Twitter, not thinking it would amount to much.
So simply for those that have yet to see it, it's such a funny take on the Innova Scandal and well worth 4 mins of your time!!
https://www.captiongenerator.com/2266511/The-Innova-story
Not a strong charter myself as I see this as very much a news driven stock, but given the recent circumstances think this may have some meaningful info.
Looking at the hour chart is this what you'd call a 'Rounding Bottom' chart pattern? See: https://ibb.co/zFDq2x9
Looks to me like it is and would fit the general sentiment that this should be rising well pretty soon.
Thanks
He's one for any budding sleuths!
Avacta's Terms and Conditions page has just been updated (20 mins ago).
See: https://avacta.com/terms-conditions/
No idea what's changed.
I guess I'm getting at there's a whole world of difference between:
"the manufacturer has been informed..."
AND
"...the manufacturer has certified the test would still be valid"
Smoke and mirrors from the NHS/MHRA/Gov
Criminal - nothing less
IMHO